BGF Research
Investment Thesis
BGF (formerly Business Growth Fund) was founded in 2011 to address the chronic SME funding gap in the UK — a shortfall first identified by the Macmillan Committee in 1931. Backed by Barclays, HSBC, Lloyds, NatWest, and Standard Chartered, BGF operates as the UK and Ireland's most active growth equity investor. The firm's core thesis is that established SMEs with strong track records and ambitious growth plans are underserved by traditional bank lending and large buyout-focused private equity firms.
BGF's model is explicitly designed to be different: it never takes controlling equity stakes, operates with an evergreen £3bn balance sheet (committing to deploy £3bn+ over the next five years), and provides patient capital without fixed exit deadlines. As of July 2026, BGF has surpassed £5bn invested, backed 600+ businesses, and completed 280+ exits.
Investment Tracks
BGF operates two distinct programmes:
Growth Stage: Patient minority equity capital for established SMEs. Initial investments of £3m-£30m, targeting businesses with £1m+ profits (or £3m+ ARR for technology companies), headquartered in the UK or Ireland. Multi-sector — Technology, Healthcare, Manufacturing, Food & Drink, Education, Climate & Sustainability, Business Services, Infrastructure, Automotive & Aerospace, Retail, Media, and more.
Early Stage: Venture capital from late seed to Series B in deep tech and life sciences. Initial investments of £3m-£10m. Sub-sectors include semiconductors/photonics, advanced materials, AI platforms, energy storage, drug discovery, MedTech, diagnostics, and advanced tools. IP protection is required. BGF has deployed £325m+ here, backing 70+ companies across 140+ transactions since 2019.
Stage Focus
- Growth Stage: Growth equity (post-revenue, profitable SMEs)
- Early Stage: Late Seed, Series A, Series B
Check Size
- Growth Stage initial: £3m-£30m (plus significant follow-on available)
- Early Stage initial: £3m-£10m
- Follow-on capital is actively provided for portfolio companies pursuing new growth opportunities; BGF has deployed £1bn+ in follow-on funding
Lead Tendency
BGF leads most of its Growth Stage investments as the primary equity partner. In Early Stage, BGF both leads (e.g. led Luffy AI's investment in July 2026) and participates alongside other investors (e.g. joined Cellular Origins' and T-Therapeutics' Series A rounds). Overall tendency: both lead and participant depending on stage and co-investor dynamics.
Recent Activity
2025 was BGF's strongest performance year: the firm returned over £600m to shareholders, achieving a money multiple above 2x across exits, and paid a £75m dividend. In 2026, the pace has remained strong.
Notable recent deals:
- July 2026: Led investment in Luffy AI (neuroplastic AI)
- July 2026: Backed Rappor (engineering and environmental consultancy, UK expansion)
- July 2026: Announced £5bn+ total investment milestone; portfolio companies generated £8.2bn in revenue growth and 35,000+ jobs
- June 2026: Gaussion raised $28m follow-on (fast EV battery charging technology)
- June 2026: Invested in TRIMTECH Therapeutics (biotech pre-clinical) and CroíValve (medical device)
- June 2026: Backed Wild Frontiers (adventure travel) and Signable (eSignature platform)
- April 2026: Exited Polar Technology (carbon-fibre manufacturer, to Trive Capital)
- April 2026: Backed Fivium (GovTech/public sector SaaS)
- March 2026: Exited Metric Search (recruiter, $100m valuation, acquired by US firm)
- March 2026: Backed Seda (pharmaceutical manufacturing, £15m)
- March 2026: Follow-on into IQ Endoscopes (medical device commercialisation)
- December 2025: Joined Cellular Origins' Series A ($40m total)
- November 2025: Joined T-Therapeutics' Series A ($91m total)
- October 2025: Announced commitment to explore fundraise for £3bn+ deployment plan
- September 2025: £10.2m into Xampla (green materials/bioplastics)
- August 2025: OrganOx achieved one of UK's largest MedTech exits, record returns for BGF
Portfolio Highlights
Notable portfolio companies (current and exited):
- OrganOx — Organ preservation MedTech (Oxford spinout, exited August 2025 as one of UK's largest MedTech exits)
- Gousto — Recipe delivery service, became UK tech unicorn ($1B+ valuation, 2020)
- Blue Light Card — Discount service for emergency services and NHS, scaled to 5M members, exited to Inflexion
- Brompton Bicycle — Iconic British folding bike manufacturer, valued at £200m at investment
- Gymbox — Premium fitness chain, £39m investment, near-doubled EBITDA
- Gaussion — UCL spinout, ultrafast EV battery charging technology (current, Early Stage)
- Caristo Diagnostics — Oxford University spinout, cardiovascular disease diagnostics (current, Early Stage)
- DEScycle — Deep Eutectic Solvents for e-waste/metals processing (current, Early Stage)
- Xampla — Green materials innovation company (Early Stage)
- Luffy AI — Neuroplastic AI (July 2026 investment)
- Kids Planet — Nursery group, 25,000+ children, exited 2021
- St Pierre Groupe — Bakery market leader, exited 2022
- Amdaris — Software development/digital transformation, exited 2023
- Hydrock — Infrastructure engineering consultancy, acquired by Stantec 2024
- M Squared — Laser/photonics (exited majority stake 2020)
Team
BGF has a large team across 14+ UK and Ireland offices:
- Andy Gregory, Chief Executive Officer — Founding member of BGF, appointed CEO in 2022. 30+ years of private equity experience at Livingbridge, Bridgepoint, and Royal Bank Development Capital.
- Ben Barker, Chief Investment Officer
- Chris Olds, Chief Operating Officer
- Claire Lamb, Head of People
- Richard Taylor, Head of Growth
- Tim Rea, Co-Head of Early Stage
- Dennis Atkinson, Co-Head of Early Stage
- Tracy Bownes, Head of Value Creation
- Paul Stevens, Head of Quoted
- Alistair Brew, Regional Investment Partner
- Barry Jackson, Regional Investment Partner
- Paddy Graham, Regional Investment Partner
- Investment Partners, Investors, and Portfolio teams based across Aberdeen, Belfast, Birmingham, Bristol, Cardiff, Cork, Dublin, Edinburgh, Leeds, London, Manchester, Newcastle, Nottingham, and Reading
Decision Process
BGF uses an investment committee structure. The Growth team is organised regionally across the UK and Ireland, with Regional Investment Partners, Investment Partners, and Investors covering each geography. The Early Stage team has two Co-Heads (Tim Rea and Dennis Atkinson) and operates as a specialist venture unit. Deals go through committee review. The scale and structure of BGF suggests multi-stage diligence with committee approval.
Founder Preferences
BGF strongly prefers:
- Ambitious founders and management teams with demonstrated growth track records
- Businesses with meaningful financial traction (£1m+ profit or £3m+ ARR for tech)
- Teams comfortable with a minority investor who will not take control
- Companies with clear, actionable growth plans: acquisitions, international expansion, product development, or talent investment
- For Early Stage: founding teams from scientific or engineering backgrounds, IP-protected innovations, university spinouts welcome
BGF has been recognised as the UK's most active institutional investor in female-founded scaleups for four consecutive years, reflecting a strong DEI commitment.
Geographic Focus
Exclusively UK and Ireland. BGF maintains 14+ offices to ensure national coverage — approximately 75% of all investments are in companies based outside London and the South East. Offices span Aberdeen, Belfast, Birmingham, Bristol, Cardiff, Cork, Dublin, Edinburgh, Leeds, London, Manchester, Newcastle, Nottingham, and Reading.
ESG
BGF is a certified UK B Corporation, member of the Diversity VC Standard, signatory of the UN Principles for Responsible Investment, and signatory of the Investing in Women Code. The firm committed to invest at least £300m in female-powered businesses via the Invest in Women Taskforce as part of its £3bn+ commitment. The BGF Foundation supports initiatives improving the lives of young people across the UK.
Backers and Structure
BGF Group PLC is backed by Barclays, HSBC, Lloyds, NatWest, and Standard Chartered. BGF Investment Management Limited is a wholly owned subsidiary, authorised and regulated by the FCA (no. 771879). The model has inspired Canadian BGF (2018) and Australian BGF (2020).